Email Updates

You are here

Promote Effective HIV Prevention Policy

AVAC’s core advocacy focus is accelerating the ethical development and global delivery of HIV prevention options, as part of a comprehensive and integrated response to the epidemic.

In alignment with that overall objective, AVAC advances critical, complementary policy goals informed by the work of our programs and the insights and advice of our global partners. Our policy goals include:

  • Robust and sustained support for HIV prevention and treatment research and implementation by bilateral, multilateral and national funders.
  • Transparency in research and implementation that incorporates engagement with and accountability to the communities where research is conducted and where HIV prevention is needed.
  • The development and funding of human-centered programs that ensure broad access to proven HIV prevention and treatment options for long-term impact.
  • Access to comprehensive sexual and reproductive health and rights.
  • Identification and elimination of the structural drivers of HIV incidence.
  • Innovative tuberculosis research and programming.
  • Comprehensive, equitable and inclusive responses to COVID-19.

Working with our global partners, and in coalitions including the Global AIDS Policy Partnership (GAPP), Federal AIDS Policy Partnership (FAPP), and the Global Health Technologies Coalition, AVAC’s current strategic policy priorities include:

  • Increasing investment in women’s HIV prevention and a collaborative global agenda to advance women’s access to integrated SRHR and HIV prevention information and services.
  • Supporting increased funding and the scale up of HIV prevention, that ensures resources for the most effective interventions, directed to the geographies and populations with the greatest need.
  • Guiding and pressuring developers, funders and policymakers to develop comprehensive access plans for all products entering the product development pipeline.
  • Engaging communities to guide the progress of new interventions through the regulatory approval and guidelines development processes.
  • Identifying and advocating for actionable, people-centered strategies to increase the uptake and continuation of HIV prevention.
  • Supporting implementation research to close the gaps in treatment and prevention.
  • Ensuring that governments, research agencies and key programs in the HIV response such as PEPFAR and the Global Fund have access to, use and share high-quality data, promote transparency on investments, programming and impact and are accountable to the communities they serve.
  • Informing the future of clinical trial design and conduct, ensuring that civil society perspectives and priorities influence current and next-generation trials and trial designs.
  • Elevating the imperative connection between prevention, treatment, research and human rights.
  • Ensuring that sound science, community engagement and the principles of health equity guide global responses to COVID-19.

Since its founding in 1995, AVAC has maintained a policy that it does not accept pharmaceutical industry funding. This policy is designed to help safeguard AVAC’s role as an independent advocate for HIV prevention and health equity, and to reduce the possibility, or any possible appearance, of conflict of interest around AVAC advocacy on issues affecting the healthcare industry. Learn more about this in the AVAC Statement on Engagement with the Pharmaceutical and Healthcare Industry.